Silence Therapeutics (SLN) Non Operating Income: 2020-2024
Historic Non Operating Income for Silence Therapeutics (SLN) over the last 3 years, with Sep 2024 value amounting to -$11.2 million.
- Silence Therapeutics' Non Operating Income fell 110193.63% to -$11.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$11.4 million, marking a year-over-year decrease of 416.68%. This contributed to the annual value of -$308,000 for FY2024, which is 7.78% up from last year.
- Per Silence Therapeutics' latest filing, its Non Operating Income stood at -$11.2 million for Q3 2024, which was down 4,738.63% from -$230,986 recorded in Q2 2024.
- In the past 5 years, Silence Therapeutics' Non Operating Income ranged from a high of $741.8 million in Q2 2021 and a low of -$732.2 million during Q1 2021.
- In the last 3 years, Silence Therapeutics' Non Operating Income had a median value of -$230,986 in 2024 and averaged -$1.9 million.
- As far as peak fluctuations go, Silence Therapeutics' Non Operating Income spiked by 99.94% in 2021, and later crashed by 110,193.63% in 2024.
- Silence Therapeutics' Non Operating Income (Quarterly) stood at $157.6 million in 2020, then spiked by 99.94% to -$88,229 in 2021, then surged by 54.58% to -$40,071 in 2022, then surged by 74.71% to -$10,133 in 2023, then tumbled by 110,193.63% to -$11.2 million in 2024.
- Its Non Operating Income stands at -$11.2 million for Q3 2024, versus -$230,986 for Q2 2024 and -$16,491 for Q1 2024.